Cargando…
Internal validation of an automated system for brachial and femoral flow mediated dilation
BACKGROUND: Flow Mediated Dilation (FMD) has immense potential to become a clinical, non-invasive biomarker of endothelial function and nitric oxide bioavailability, which regulate vasomotor activity. Unfortunately, FMD analysis techniques could deviate significantly in different laboratories if a v...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568717/ https://www.ncbi.nlm.nih.gov/pubmed/28852570 http://dx.doi.org/10.1186/s40885-017-0073-1 |
_version_ | 1783258882064252928 |
---|---|
author | Ratcliffe, Brycen Pawlak, Robert Morales, Francisco Harrison, Caleb Gurovich, Alvaro N. |
author_facet | Ratcliffe, Brycen Pawlak, Robert Morales, Francisco Harrison, Caleb Gurovich, Alvaro N. |
author_sort | Ratcliffe, Brycen |
collection | PubMed |
description | BACKGROUND: Flow Mediated Dilation (FMD) has immense potential to become a clinical, non-invasive biomarker of endothelial function and nitric oxide bioavailability, which regulate vasomotor activity. Unfortunately, FMD analysis techniques could deviate significantly in different laboratories if a validation process is not involved. The purpose of this study was to provide validation to the assessment of FMD analysis in our laboratory and to standardize this process before reporting results of FMD. METHODS: Brachial and femoral arteries FMD were performed on 28 apparently healthy participants (15 male and 13 female, ages 18–35 years). For the intratester reliability study, nine subjects were asked to come to the lab for a second brachial FMD within 48 h. All FMD procedures were performed by the same investigator, while the FMD analyses were performed by 2 independent testers who were blind to each other’s analyses. FMD analyses included baseline artery diameter measurements, peak artery diameter after 5 min of ischemia, and FMD. Analysis was completed via an automated edge detection system by both testers after training of the methodical process of analysis to minimize variability. Intratester and intertester reliability were determined by using coefficient of variation (CV) between first and second visit (intratester) and between results obtained by both testers (intertester). RESULTS: The intratester CVs for tester 1 and 2 were 3.28 and 2.62%, 3.74 and 3.27%, and 4.95 and 2.38% for brachial baseline artery diameter, brachial peak artery dilation, and brachial FMD, respectively. In the intertester CVs were 2.40, 3.16, and 3.37% for brachial baseline artery diameter, peak artery dilation, and FMD, respectively and 4.52, 5.50, and 3.46% for femoral baseline artery diameter, peak artery dilation, and FMD, respectively. CONCLUSION: All CVs were under or around 5%, confirming a strong reliability of the method. Our laboratory has shown that the FMD protocol is reproducible due to the significantly low coefficient of variation. This is one step closer to use FMD as a biomarker for endothelial function in our laboratory. |
format | Online Article Text |
id | pubmed-5568717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55687172017-08-29 Internal validation of an automated system for brachial and femoral flow mediated dilation Ratcliffe, Brycen Pawlak, Robert Morales, Francisco Harrison, Caleb Gurovich, Alvaro N. Clin Hypertens Research BACKGROUND: Flow Mediated Dilation (FMD) has immense potential to become a clinical, non-invasive biomarker of endothelial function and nitric oxide bioavailability, which regulate vasomotor activity. Unfortunately, FMD analysis techniques could deviate significantly in different laboratories if a validation process is not involved. The purpose of this study was to provide validation to the assessment of FMD analysis in our laboratory and to standardize this process before reporting results of FMD. METHODS: Brachial and femoral arteries FMD were performed on 28 apparently healthy participants (15 male and 13 female, ages 18–35 years). For the intratester reliability study, nine subjects were asked to come to the lab for a second brachial FMD within 48 h. All FMD procedures were performed by the same investigator, while the FMD analyses were performed by 2 independent testers who were blind to each other’s analyses. FMD analyses included baseline artery diameter measurements, peak artery diameter after 5 min of ischemia, and FMD. Analysis was completed via an automated edge detection system by both testers after training of the methodical process of analysis to minimize variability. Intratester and intertester reliability were determined by using coefficient of variation (CV) between first and second visit (intratester) and between results obtained by both testers (intertester). RESULTS: The intratester CVs for tester 1 and 2 were 3.28 and 2.62%, 3.74 and 3.27%, and 4.95 and 2.38% for brachial baseline artery diameter, brachial peak artery dilation, and brachial FMD, respectively. In the intertester CVs were 2.40, 3.16, and 3.37% for brachial baseline artery diameter, peak artery dilation, and FMD, respectively and 4.52, 5.50, and 3.46% for femoral baseline artery diameter, peak artery dilation, and FMD, respectively. CONCLUSION: All CVs were under or around 5%, confirming a strong reliability of the method. Our laboratory has shown that the FMD protocol is reproducible due to the significantly low coefficient of variation. This is one step closer to use FMD as a biomarker for endothelial function in our laboratory. BioMed Central 2017-08-22 /pmc/articles/PMC5568717/ /pubmed/28852570 http://dx.doi.org/10.1186/s40885-017-0073-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Ratcliffe, Brycen Pawlak, Robert Morales, Francisco Harrison, Caleb Gurovich, Alvaro N. Internal validation of an automated system for brachial and femoral flow mediated dilation |
title | Internal validation of an automated system for brachial and femoral flow mediated dilation |
title_full | Internal validation of an automated system for brachial and femoral flow mediated dilation |
title_fullStr | Internal validation of an automated system for brachial and femoral flow mediated dilation |
title_full_unstemmed | Internal validation of an automated system for brachial and femoral flow mediated dilation |
title_short | Internal validation of an automated system for brachial and femoral flow mediated dilation |
title_sort | internal validation of an automated system for brachial and femoral flow mediated dilation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568717/ https://www.ncbi.nlm.nih.gov/pubmed/28852570 http://dx.doi.org/10.1186/s40885-017-0073-1 |
work_keys_str_mv | AT ratcliffebrycen internalvalidationofanautomatedsystemforbrachialandfemoralflowmediateddilation AT pawlakrobert internalvalidationofanautomatedsystemforbrachialandfemoralflowmediateddilation AT moralesfrancisco internalvalidationofanautomatedsystemforbrachialandfemoralflowmediateddilation AT harrisoncaleb internalvalidationofanautomatedsystemforbrachialandfemoralflowmediateddilation AT gurovichalvaron internalvalidationofanautomatedsystemforbrachialandfemoralflowmediateddilation |